169881-55-4

Basic information

• Product Name: {2-[(2-bromo-4-isopropyl-phenyl)-ethyl-amino]-6-methyl-pyrimidin-4-yl}-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone
• CAS NO: 169881-55-4
• Molecular Weight: 524.463
• Mol File: 169881-55-4.mol

Chemical Properties

• CAS DataBase Reference: {2-[(2-bromo-4-isopropyl-phenyl)-ethyl-amino]-6-methyl-pyrimidin-4-yl}-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone(CAS DataBase Reference)
• NIST Chemistry Reference: {2-[(2-bromo-4-isopropyl-phenyl)-ethyl-amino]-6-methyl-pyrimidin-4-yl}-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone(169881-55-4)
• EPA Substance Registry System: {2-[(2-bromo-4-isopropyl-phenyl)-ethyl-amino]-6-methyl-pyrimidin-4-yl}-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone(169881-55-4)

Safety Data

• Hazardous Substances Data: 169881-55-4(Hazardous Substances Data)

Upstream product

• 257615-17-1 2-(N-(2-bromo-4-(2-propyl)phenyl)amino)-4-carbomethoxy-6-methylpyrimidinamine 
• 89793-11-3 methyl 2-chloro-6-methylpyrimidine-4-carboxylate 
• 169880-48-2 methyl 2-((2-bromo-4-(1-methylethyl)phenyl)ethylamino)-6-methyl-4-pyrimidinecarboxylate 
• 34803-68-4 1-(pyrazin-2-yl)piperazine 

Relevant articles and documents

Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists

Structure-activity studies around the 4-position of 2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists suggest that there is a large lipophilic cavity in the rat CRF receptor, which can accommodate a wide variety of substituents at this position in contrast to the steric constraints observed for other positions on the 2-anilinopyrimidine core. The chemical syntheses and biological activities of 2-anilinopyrimidine CRF antagonists with carbon-linked substituents at the 4-position are reported. Significant improvements in rat pharmacokinetic parameters were achieved relative to those for the lead structure. While the lead compound 1 (rCRF K(i) = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (ip) or oral (po) dosing, compounds 3-3 (rCRF K(i) = 16 nM) and 3-4 (rCRF K(i) = 59 nM) gave high rat plasma levels at 30 mg/kg (ip, po) (C(max) = 1389 nM and 8581 nM (ip) respectively; C(max) = 113 nM and 988 nM (po), respectively). Furthermore 3-3 and 3-4 had superior bioavailabilities at these doses (59 and 46% (ip), respectively; 2 and 10% (po), respectively). (C) 1999 DuPont Pharmaceuticals Company.